Result of AGM
RNS & Investor News
SweetBiotix®: Evaluation agreement with global dairy company
31 May 2018
OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol and diabetes, announces that it has entered into an evaluation agreement with a global dairy company for its SweetBiotix® calorie free sweet fibres. The agreement grants a non-exclusive license for an evaluation period to explore the potential for using the SweetBiotix® technology to reduce the sugar content in a range of its dairy food products.
OptiBiotix has previously announced (RNS: 27 March 2018) that the five successful human taste studies on the SweetBiotix® product development had created interest from a number of corporates with expertise in the manufacture and commercialisation of speciality ingredients and/or consumer products. This agreement reflects interest from one of these companies in exploring the use of SweetBiotix® in its branded dairy products.
The company is a global brand and one of the world's largest providers of dairy products with an annual turnover exceeding $10bn. The details of the evaluation and terms of the agreement are confidential and no further details can be disclosed. A further announcement will be made in due course.
Stephen O'Hara, CEO of OptiBiotix, commented: "We are pleased to announce the signing of this agreement for SweetBiotix® with one of the world's largest dairy companies and such a well-known global brand. This is part of a strategy of working with global partners who have the capability and expertise to manufacture speciality ingredients like SweetBiotix® and well-known consumer brands who have the specialist application expertise to incorporate this technology into their own branded breaded, dairy, cereal and beverage consumer products. This approach provides a low risk way to fully exploit the wide range of opportunities offered by our SweetBiotix® technology."
For further information, please contact:
|OptiBiotix Health plc
Stephen O'Hara, Chief Executive
Contact via Walbrook below
|Cairn Financial Advisers LLP (NOMAD)
Liam Murray / Jo Turner
|Tel: 020 7213 0880|
Adrian Hargrave / Scott Mathieson / Kate Bannatyne (Corporate Finance)
|Tel: 020 7220 0500|
|Walbrook PR Ltd
|Tel: 020 7933 8780 or [email protected]
Mob: 07876 741 001
About OptiBiotix - www.optibiotix.com
OptiBiotix was formed in March 2012 to develop compounds which modify the human microbiome - the collective genome of the microbes in the body - to prevent and manage human disease.
The aim of OptiBiotix is to discover and develop microbial strains, compounds and formulations, which modulate the human microbiome and can be used as food ingredients and supplements or active compounds for the prevention and management of human metabolic diseases, examples of which include obesity, cholesterol and lipid distribution and diabetes.
OptiBiotix has established a pipeline of microbiome modulators that can impact on lipid and cholesterol management, energy harvest and appetite suppression. The development pipeline is fuelled by its proprietary OptiScreen® and OptiBiotic® platform technologies designed to identify metabolic pathways and compounds that impact on human physiology and bring potential health benefits. These platforms are applicable across a wider range of other human diseases.
OptiBiotix Health secures significant exclusive licence agreement for OptiBiome
Stephen O'Hara | 01 Apr 2020